--- title: "LENZ Therapeutics sells 1,748,634 shares at $45.75 in $80,000,000 block trade" url: "https://aibio.space/news/lenz-therapeutics-sells-1-748-634-shares-45-75-80-000-000-block-trade/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-10-08" section: "Financings" tickers: "NASDAQ:LENZ" source: "https://www.sec.gov/Archives/edgar/data/1815776/000181577625000064/lenz-20251008.htm" summary: "The sale to a single investor was made under the company's at-the-market agreement with TD Securities (USA) LLC. LENZ reported the 1,748,634 shares sold at" --- By the aibio.space news desk. Sources - [LENZ Therapeutics, Inc. 8-K (2025-10-08)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000064/lenz-20251008.htm) [LENZ](https://aibio.space/companies/lenz-therapeutics/) 2025-10-08 # LENZ Therapeutics sells 1,748,634 shares at $45.75 in $80,000,000 block trade Tickers [LENZ](https://aibio.space/companies/lenz-therapeutics/) The sale to a single investor was made under the company's at-the-market agreement with TD Securities (USA) LLC. LENZ reported the 1,748,634 shares sold at $45.75 in an 8-K filed October 8, 2025. ## Key facts - **Company**: LENZ Therapeutics, Inc. (NASDAQ: LENZ) - **News type**: Financings - **Primary source**: [LENZ Therapeutics, Inc. 8-K (2025-10-08)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000064/lenz-20251008.htm) *The lower Manhattan skyline. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The block sale LENZ Therapeutics, Inc. (Nasdaq: [LENZ](https://aibio.space/companies/lenz-therapeutics/)) sold 1,748,634 shares of common stock on October 7, 2025 at $45.75 per share, for gross proceeds of approximately $80,000,000. It disclosed the sale in a Form 8-K dated October 8, 2025. The 8-K describes the sale as a block trade to a single investor, which the company does not name. A block trade is a large sale negotiated as one transaction rather than spread out through the market over time. LENZ made the sale under its at-the-market Sales Agreement with TD Securities (USA) LLC, dated as of April 4, 2025. Under that kind of agreement a company sells registered shares through a sales agent, and the 8-K says the sale was made under and subject to the terms of that agreement. A copy of the agreement was filed with an 8-K on April 4, 2025. The 8-K names TD Securities (USA) LLC as the sales agent and names no other adviser or counsel on the sale. The company is an emerging growth company, and the 8-K is signed by Chief Financial Officer Daniel Chevallard. ## The product and its trial record LENZ describes itself as a pre-commercial biopharmaceutical company focused on presbyopia, the loss of near vision that affects nearly all people over 45. Its 10-K filed in March 2025 puts the U.S. presbyopic population at 128 million and gives a U.S. market opportunity for a once-daily drop of more than $3 billion. Those are the company's estimates. The lead candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine. In its Phase 3 CLARITY 1 and CLARITY 2 trials, the company says LNZ100 achieved its primary and key secondary endpoints, with statistically significant three-line or greater improvement in near vision without losing distance acuity. In the vehicle-controlled CLARITY 2 trial, the company reported that 71% of patients reached three-line or greater improvement at 3 hours on day 1, which it labels the primary endpoint, and 40% at 10 hours. Those are company-reported results from two four-week trials, and the company itself says the results were reproducible across both studies over that period. The company's own figures put the share reaching that improvement at 10 hours, 40%, below the share at 3 hours, 71%. The company says LNZ100 showed no serious treatment-related adverse events across more than 30,000 treatment days, including a six-month long-term safety trial called CLARITY 3. ## The competing drug and the regulatory timeline The 10-K describes Vuity, marketed by AbbVie, as the only approved and marketed pharmaceutical treatment for presbyopia. It says Vuity's uptake has been limited by reportedly lower-than-expected efficacy and duration of effect, and by rare retinal tears and detachments. A label amendment reflects that retinal risk. LENZ says its drug is designed to avoid blurry distance vision, a limitation it attributes to other miotics. LENZ submitted a New Drug Application for LNZ100 in August 2024. The 10-K says the FDA set a target action date of August 8, 2025, and the company expected a launch in the fourth quarter of 2025 if the drug was approved. The 10-K also says the company expected five years of new chemical entity exclusivity in the United States if approved. That target date had passed by the time of this sale, and the 8-K does not say how the FDA ruled. ## What the money is for The 8-K does not state a use of the sale proceeds, and the gross figure is before the agent's commissions and expenses. The 8-K gives no cash balance, so the proceeds cannot be set against one. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story LENZ LENZ Therapeutics, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/lenz-therapeutics-sells-1-748-634-shares-45-75-80-000-000-block-trade/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "LENZ Therapeutics sells 1,748,634 shares at $45.75 in $80,000,000 block trade", 2025-10-08, https://aibio.space/news/lenz-therapeutics-sells-1-748-634-shares-45-75-80-000-000-block-trade/